PRECIGEN, INC. Stock-Based Compensation
PRECIGEN, INC. (PGEN) reported Stock-Based Compensation of $6.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- PRECIGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.58M, a 118.56% increase year-over-year.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.01M, a 12.29% increase year-over-year.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.16M, a 24.50% decline year-over-year.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.39M, a 112.91% increase year-over-year.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $10.87M, a 14.73% increase from fiscal 2024.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $9.47M, a 4.22% decline from fiscal 2023.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $9.89M, a 3.12% decline from fiscal 2022.
- PRECIGEN, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $10.21M, a 26.60% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $6.59M 10-Q · filed 2026-08-04 | $8.75M derived: sum of 3 quarters · filed 2026-08-04 | $13.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.01M 10-Q · filed 2026-05-13 | $5.17M derived: sum of 2 quarters · filed 2026-05-13 | $9.56M derived: sum of 3 quarters · filed 2026-05-13 | $11.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $6.55M derived: sum of 2 quarters · filed 2026-03-25 | $8.19M derived: sum of 3 quarters · filed 2026-08-04 | $10.87M 10-K · filed 2026-03-25 |
| 2025-09-30 | $4.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.03M derived: sum of 2 quarters · filed 2026-08-04 | $8.70M 10-Q · filed 2025-11-13 | $11.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.32M 10-Q · filed 2026-08-04 | $7.18M derived: sum of 3 quarters · filed 2026-08-04 | $9.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.68M 10-Q · filed 2026-05-13 | $5.54M derived: sum of 2 quarters · filed 2026-05-13 | $7.60M derived: sum of 3 quarters · filed 2026-05-13 | $9.57M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.93M derived: sum of 2 quarters · filed 2026-03-25 | $6.89M derived: sum of 3 quarters · filed 2026-03-25 | $9.47M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.03M derived: sum of 2 quarters · filed 2025-11-13 | $6.61M 10-Q · filed 2025-11-13 | $8.87M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $4.54M 10-Q · filed 2025-08-12 | $6.81M derived: sum of 3 quarters · filed 2026-03-25 | $9.11M derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | $2.58M 10-Q · filed 2025-05-14 | $4.84M derived: sum of 2 quarters · filed 2026-03-25 | $7.15M derived: sum of 3 quarters · filed 2026-03-25 | $9.34M derived: sum of 4 quarters · filed 2026-03-25 |
| 2023-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.57M derived: sum of 2 quarters · filed 2026-03-25 | $6.76M derived: sum of 3 quarters · filed 2026-03-25 | $9.89M 10-K · filed 2026-03-25 |
| 2023-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $4.50M derived: sum of 2 quarters · filed 2024-11-14 | $7.63M 10-Q · filed 2024-11-14 | $9.84M derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.32M 10-Q · filed 2024-08-14 | $7.53M derived: sum of 3 quarters · filed 2025-03-19 | $9.65M derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-03-31 | $3.13M 10-Q · filed 2024-05-14 | $5.34M derived: sum of 2 quarters · filed 2025-03-19 | $7.47M derived: sum of 3 quarters · filed 2025-03-19 | $9.78M derived: sum of 4 quarters · filed 2025-03-19 |
| 2022-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $4.33M derived: sum of 2 quarters · filed 2025-03-19 | $6.64M derived: sum of 3 quarters · filed 2025-03-19 | $10.21M 10-K · filed 2025-03-19 |
| 2022-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.43M derived: sum of 2 quarters · filed 2023-11-09 | $8.00M 10-Q · filed 2023-11-09 | $10.44M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $5.87M 10-Q · filed 2023-08-09 | $8.31M derived: sum of 3 quarters · filed 2024-03-19 | $10.80M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $3.56M 10-Q · filed 2023-05-10 | $6.00M derived: sum of 2 quarters · filed 2024-03-19 | $8.49M derived: sum of 3 quarters · filed 2024-03-19 | $12.05M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $4.93M derived: sum of 2 quarters · filed 2024-03-19 | $8.49M derived: sum of 3 quarters · filed 2024-03-19 | $13.90M 10-K · filed 2024-03-19 |
| 2021-09-30 | $2.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.05M derived: sum of 2 quarters · filed 2022-11-09 | $11.46M 10-Q · filed 2022-11-09 | $15.96M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $8.97M 10-Q · filed 2022-08-08 | $13.47M derived: sum of 3 quarters · filed 2023-03-06 | $18.07M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $5.42M 10-Q · filed 2022-05-09 | $9.91M derived: sum of 2 quarters · filed 2023-03-06 | $14.51M derived: sum of 3 quarters · filed 2023-03-06 | $19.41M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $9.10M derived: sum of 2 quarters · filed 2023-03-06 | $13.99M derived: sum of 3 quarters · filed 2023-03-06 | $18.37M 10-K · filed 2023-03-06 |
| 2020-09-30 | $4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $9.50M derived: sum of 2 quarters · filed 2021-11-08 | $13.87M 10-Q · filed 2021-11-08 | $18.28M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $4.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $9.27M 10-Q · filed 2021-08-09 | $13.68M derived: sum of 3 quarters · filed 2022-03-01 | $19.10M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $4.37M 10-Q · filed 2021-05-10 | $8.78M derived: sum of 2 quarters · filed 2022-03-01 | $14.21M derived: sum of 3 quarters · filed 2022-03-01 | $14.27M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $9.84M derived: sum of 2 quarters · filed 2022-03-01 | $9.90M derived: sum of 3 quarters · filed 2022-03-01 | $18.95M 10-K · filed 2022-03-01 |
| 2019-09-30 | $5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $5.48M derived: sum of 2 quarters · filed 2020-11-09 | $14.54M 10-Q · filed 2020-11-09 | $22.49M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $9.12M 10-Q · filed 2020-08-10 | $17.07M derived: sum of 3 quarters · filed 2021-03-01 | $25.20M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $9.05M 10-Q · filed 2020-05-11 | $17.01M derived: sum of 2 quarters · filed 2021-03-01 | $25.14M derived: sum of 3 quarters · filed 2021-03-01 | $33.99M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.09M derived: sum of 2 quarters · filed 2021-03-01 | $24.93M derived: sum of 3 quarters · filed 2021-03-01 | $36.30M 10-K · filed 2021-03-01 |
| 2018-09-30 | $8.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $16.98M derived: sum of 2 quarters · filed 2019-11-12 | $28.34M 10-Q · filed 2019-11-12 | $37.97M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $8.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $20.21M 10-Q · filed 2019-08-09 | $29.84M derived: sum of 3 quarters · filed 2020-03-02 | $41.89M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $11.36M 10-Q · filed 2019-05-09 | $20.99M derived: sum of 2 quarters · filed 2020-03-02 | $33.05M derived: sum of 3 quarters · filed 2020-03-02 | $45.04M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $21.68M derived: sum of 2 quarters · filed 2020-03-02 | $33.68M derived: sum of 3 quarters · filed 2020-03-02 | $41.58M 10-K · filed 2020-03-02 |
| 2017-09-30 | $12.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $24.05M derived: sum of 2 quarters · filed 2018-11-08 | $31.95M 10-Q · filed 2018-11-08 | $43.52M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | $12.00M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-13 | $19.89M 10-Q · filed 2018-08-13 | $31.46M derived: sum of 3 quarters · filed 2019-03-01 | $42.26M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | $7.89M 10-Q/A · filed 2018-08-13 | $19.46M derived: sum of 2 quarters · filed 2019-03-01 | $30.26M derived: sum of 3 quarters · filed 2019-03-01 | $36.91M derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $22.36M derived: sum of 2 quarters · filed 2019-03-01 | $29.01M derived: sum of 3 quarters · filed 2019-03-01 | $42.20M 10-K · filed 2019-03-01 |
| 2016-09-30 | $10.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $17.44M derived: sum of 2 quarters · filed 2017-11-09 | $30.63M 10-Q · filed 2017-11-09 | $42.77M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $6.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $19.84M 10-Q · filed 2017-08-09 | $31.98M derived: sum of 3 quarters · filed 2018-03-01 | $40.37M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $13.19M 10-Q · filed 2017-05-10 | $25.33M derived: sum of 2 quarters · filed 2018-03-01 | $33.72M derived: sum of 3 quarters · filed 2018-03-01 | $41.60M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $12.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $20.53M derived: sum of 2 quarters · filed 2018-03-01 | $28.41M derived: sum of 3 quarters · filed 2018-03-01 | $38.67M 10-K · filed 2018-03-01 |
| 2015-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $16.27M derived: sum of 2 quarters · filed 2016-11-09 | $26.52M 10-Q · filed 2016-11-09 | $33.50M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $7.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $18.14M 10-Q · filed 2016-08-09 | $25.12M derived: sum of 3 quarters · filed 2017-03-01 | $29.37M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $10.26M 10-Q · filed 2016-05-10 | $17.24M derived: sum of 2 quarters · filed 2017-03-01 | $21.49M derived: sum of 3 quarters · filed 2017-03-01 | $28.33M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $6.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $11.23M derived: sum of 2 quarters · filed 2017-03-01 | $18.07M derived: sum of 3 quarters · filed 2017-03-01 | $21.85M 10-K · filed 2017-03-01 |
| 2014-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $11.10M derived: sum of 2 quarters · filed 2015-11-09 | $14.87M 10-Q · filed 2015-11-09 | $15.95M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $6.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $10.62M 10-Q · filed 2015-08-10 | $11.70M derived: sum of 3 quarters · filed 2016-02-29 | $12.35M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $3.77M 10-Q · filed 2015-05-11 | $4.85M derived: sum of 2 quarters · filed 2016-02-29 | $5.50M derived: sum of 3 quarters · filed 2016-02-29 | $6.31M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.73M derived: sum of 2 quarters · filed 2016-02-29 | $2.53M derived: sum of 3 quarters · filed 2016-02-29 | $2.92M 10-K · filed 2016-02-29 |
| 2013-09-30 | $645.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $1.45M derived: sum of 2 quarters · filed 2014-11-13 | $1.84M 10-Q · filed 2014-11-13 | $2.34M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.20M 10-Q · filed 2014-08-14 | $1.70M derived: sum of 3 quarters · filed 2015-03-02 | $2.13M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $387.00K 10-Q · filed 2014-05-09 | $886.00K derived: sum of 2 quarters · filed 2015-03-02 | $1.32M derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $938.00K derived: sum of 2 quarters · filed 2015-03-02 | $1.46M 10-K · filed 2015-03-02 | |
| 2012-09-30 | $439.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | $959.00K 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | $520.00K 10-Q/A · filed 2013-10-21 | |||
| 2011-12-31 | $983.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |